OncoCyte Corp Human Resources Contracts & Agreements
24 Contracts & Agreements
- Bonus & Incentive Agreements (1 contract)
- Change of Control Agreements (4)
- Consulting Agreements (2)
- Employment Agreements (12)
- Separation Agreements (4)
- Transition Agreements (1)
- Employment Agreement, dated June 17, 2024, by and between Oncocyte Corporation and Andrea James (Filed With SEC on August 8, 2024)
- Employment Agreement, dated May 20, 2024, by and between Oncocyte Corporation and Ekkehard Schtz (Filed With SEC on August 8, 2024)
- Amendment to Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated July 13, 2023 (Filed With SEC on July 14, 2023)
- Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated June 6, 2023 (Filed With SEC on June 9, 2023)
- Consulting Agreement, by and between the Company and Douglas Ross, dated as of December 16, 2022 (Filed With SEC on December 21, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Douglas Ross, dated December 16, 2022 (Filed With SEC on December 21, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Gisela Paulsen, dated December 16, 2022 (Filed With SEC on December 21, 2022)
- Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)
- Employment Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)
- Consulting Agreement, by and between the Company and Ronald Andrews, dated as of December 1, 2022 (Filed With SEC on December 5, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Ronald Andrews, dated December 1, 2022 (Filed With SEC on December 5, 2022)
- Change in Control and Executive Severance Plan Agreement, dated October 4 2021, between Oncocyte Corporation and Gisela Paulsen (Filed With SEC on October 7, 2021)
- Amendment of 2018 Equity Incentive Plan (Filed With SEC on June 28, 2021)
- Employment Agreement, dated March 23, 2020, between OncoCyte Corporation and Douglas Ross (Filed With SEC on July 29, 2020)
- Form of Change in Control and Severance Agreement (Filed With SEC on March 26, 2020)
- Oncocyte Corporation Change in Control and Severance Plan (Filed With SEC on March 26, 2020)
- Employment Agreement, dated May 22, 2019, between OncoCyte Corporation and Padma Sundar (Filed With SEC on March 26, 2020)
- Transition Agreement, dated July 1, 2019, between OncoCyte Corporation and William Annett (Filed With SEC on July 8, 2019)
- Employment Agreement, dated June 4, 2019, between OncoCyte Corporation and Ronald Andrews (Filed With SEC on June 6, 2019)
- Separation Agreement, dated January 22, 2019, between OncoCyte Corporation and Kristine Mechem (Filed With SEC on April 1, 2019)
- Employment Agreement, dated August 6, 2018, between OncoCyte Corporation and Albert P. Parker (Filed With SEC on November 13, 2018)
- Employment Agreement, dated August 31, 2017, between OncoCyte Corporation and Michael Vicari (Filed With SEC on April 2, 2018)
- Employment Agreement, dated November 15, 2017, between OncoCyte Corporation and Mitchell Levine (Filed With SEC on April 2, 2018)
- Employment Agreement, dated November 1, 2016, between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on February 27, 2017)
